Halometasone/triclosan cream: (Sicorten plus). A study of clinical and allergological behaviour

The clinical efficacy and safety, and the allergic potential of Sicorten Plus cream (0.05% halometasone, 1% triclosan) was investigated in an open trial of 21 days' duration in patients suffering from infected eczematous dermatitis. The cream was applied twice daily (morning and evening) in a thin layer with or without light occlusive dressing. The onset of therapeutic efficacy was observed, on average, after 9.5 days; subjective signs and symptoms significantly improved during the trial (ANOVA P <0.001). Most patients (92%) were completely cured in 21 days. Cosmetic acceptability of the cream was satisfactory. Only two patients dropped-out because of a severe burning sensation. No allergic reactions either with the ordinary patch test or the photopatch test were observed.